Cancer Core Europe’s Post

🔵 The #THRIVE project by the European Union, focusing on liver cancer research for both children and adults, was launched with a meeting in Barcelona on 12 January 2024. Led by Josep M. Llovet of the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and partnered with the Germans Trias i Pujol Research Institute (IGTP)'s Childhood Liver Oncology group (cLOG) under Carolina Armengol, the project aims to leverage their expertise in liver cancer. ☑ Budget of €12 million and13 organisations from eight European countries involved. ☑ Advancing liver cancer care through collaborative research and innovation. Learn more: https://lnkd.in/dBpXCAVF THRIVE liver cancer European Health and Digital Executive Agency (HaDEA) #THRIVEProject #LiverCancerResearch #EuropeanUnion #InnovationInHealthcare

Dr. Hatim Sabaawy, a leader at the University of Colorado Cancer Center, has received a $750K grant from the National Cancer Institute (NCI) to advance lung cancer research. This project aims to create innovative models for testing immunotherapies, particularly for non-small cell lung cancer, which makes up 80-85% of all lung cancers. By developing more accurate and personalized testing methods, Dr. Sabaawy’s work has the potential to transform how we approach cancer treatment, bringing us closer to more effective and tailored therapies for patients. This research is a true cross-campus collaboration, involving experts from multiple University of Colorado Anschutz Medical Campus departments and institutes. The first grant is just the beginning, with hopes for additional funding to expand this vital work. Together, we’re pushing the boundaries of what’s possible in cancer research and patient care. https://bit.ly/3TcoKGU #CancerResearch #LungCancer #Medicine #CUAnschutz

🔬Breaking Medical News 🔬 Pilot Study Shows Promise in Treating Chordoma! A study led by Dr. Santosh Kesari, Director of Neuro-oncology at Pacific Neuroscience Institute (PNI) and Saint John’s Cancer Institute, has just unveiled groundbreaking findings in the Clinical Cancer Research journal. Conducted at Providence Saint John’s Health Center, this research focuses on chordomas, a rare cancer affecting the spine and skull base. Patients in this study underwent treatment with pemetrexed, a multi-pronged anti-folate chemotherapy commonly used in treating various cancers. Two of the 14 patients in the study experienced significant tumor shrinkage, seven additional patients experienced minor tumor shrinkage, and the majority experienced improvements in their symptoms. Dr. Kesari commented, "We plan to build on this framework of pemetrexed and combine it with other drugs, including immunotherapy, in future clinical trials.” Join us in congratulating Dr. Kesari and the team for their remarkable breakthrough, marking a significant milestone on the journey towards advancing patient care. 📊🧪 Learn more: https://lnkd.in/g7a3t_8C #MedicalBreakthrough #CancerResearch #HealthcareInnovation

Cancer Cell Impact Factor: Unveiling the Intricacies of Cancer Cell Impact Factor: Fitlifejourney:Explore the cutting-edge world of cancer research through the lens of Cancer Cell, a renowned scientific journal with a high impact factor. Delve into innovative studies, global collaborations, and translational research that make Cancer Cell a hub for groundbreaking discoveries in the fight against cancer. Uncover the intricacies of its impact factor and understand why this journal stands out in shaping the landscape of cancer science. Read more for blog post, 👇👇 https://lnkd.in/d4WMur5e

The cancer patients who participate in clinical trials are the frontlines of finding more effective treatments. #clinicaltrials #oncologytrials #cancerresearch #oncology

Exciting breakthrough in the fight against pancreatic cancer! 🌟 A research team, led by Dan Theodorescu, M.D., Ph.D., director of Cedars-Sinai Cancer in Los Angeles, California, has developed an innovative approach using artificial intelligence (AI) to enhance precision medicine. Their groundbreaking study, published in January 2024 in Nature Cancer, introduces the Molecular Twin Precision Oncology Platform (MT-POP). This cutting-edge technology has identified biomarkers that outperform the current FDA-approved pancreatic cancer test, CA 19-9, in predicting pancreatic cancer survival. This advancement holds great promise for improving patient outcomes and revolutionizing pancreatic cancer diagnosis and treatment. Kudos to Dr. Theodorescu and his team for their remarkable contributions to the field of oncology! 🩺💡 #PancreaticCancer #PrecisionMedicine #AI #MedicalInnovation

Bridging the Gap: A Pan-European Perspective on the Changing Treatment Landscape for Early-stage Non-small Cell Lung Cancer The development of novel immunotherapeutic and molecular targeted treatments for patients with early-stage non-small cell lung cancer has rapidly amplified over the past several years, signaling an imminent shift in treatment paradigms. While these changes offer new hope, they also raise questions about cost and accessibility. Two collaborative publications, led by Amsterdam UMC - Cancer Center Amsterdam researchers and recently published in The Lancet Regional Health Europe, examine this shifting medical landscape, and identify an urgent need for a collective approach to ensure that all patients across Europe have access to the best possible care. Read more on our website: https://lnkd.in/e6EsWcgy Amsterdam UMC - Cancer Center Amsterdam, Amsterdam UMC, #LungCancer #CancerCare #CancerResearch

I am encouraged by the progress in lung cancer treatment, particularly with Radiopharm Theranostics' RAD 204. The approval for human trials at multiple sites indicates significant advancement in addressing advanced non-small cell lung cancer (NSCLC). RAD 204's unique approach targeting PD-L1 positive expression using lutetium-177 radioisotope is promising for theranostic medicine. Collaboration with Lantheus for NM-01 development further emphasizes the commitment to personalized medicine in lung cancer care. With the high incidence of lung cancer cases globally, these developments offer hope for improved outcomes, but rigorous research is vital for realizing their full potential. #lungscreen #research #radiology

🔬 **Advancing Precision Oncology at Hadassah** 🔬 We are thrilled and proud to announce a groundbreaking partnership of Hadassah Medical Center Sharett Oncology Institute and HCRI HADASSAH CANCER RESEARCH INSTITUTE with Pangea Biomed and Ultima Genomics aimed to revolutionize the solid tumors trearment predictions. Read the full article here: https://lnkd.in/guVHyXqN As part of this collaboration Hadassah will provide access to essential biological samples accompanied by clinical data and comprehensive expert analysis. Through this initiative the data shall undergo processing by cutting-edge Pangea’s #ENLIGHT platform and Ultima Genomics' advanced sequencing. Empowering our oncologists to deliver more personalized and effective cancer treatments. This collaboration underscores Hadassah's commitment to leading the future of cancer care through innovation and research excellence. Aron Popovtzer Tuvik Beker Amalia Herszkowicz Tamar Raz Nadav Askari, Ph.D. Tzahi Neuman #PrecisionOncology #CancerResearch #HadassahMedicalCenter #HealthcareInnovation

Partnerships are at the 💗 of what we do at @Omico to bring access to precision oncology across the nation. Great to have this connection with @QUT and @AGTC to improve access for Queenslanders. #PrecisionOncology #CancerMeetsItsMatch #Omico